Skip to main content

Table 2 Association of PON1 Q192R polymorphism with glycemia, insulin secretion, and sensitivity after stratified analysis by statin therapy

From: The gene–treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry

   FPG, mmol/l HbA1c, % (mmol/mol) Logarithm of C-peptide Logarithm of HOMA2-%β Logarithm of HOMA2-IR
Statin (−) QQ 7.75 ± 2.02 7.23 ± 0.95 (55.5 ± 10.4) 0.19 ± 0.39 3.69 ± 0.45 0.02 ± 0.43
QR 7.66 ± 2.04 7.28 ± 1.03 (56.1 ± 11.2) 0.16 ± 0.38 3.69 ± 0.48 −0.02 ± 0.41
RR 7.73 ± 2.06 7.35 ± 1.05 (56.8 ± 11.5) 0.19 ± 0.39 3.69 ± 0.50 0.01 ± 0.41
P value 0.82 0.07 0.47 0.8 0.47
Statin (+) QQ 7.51 ± 1.79 7.34 ± 0.92 (56.7 ± 10.1)# 0.27 ± 0.40# 3.80 ± 0.49# 0.09 ± 0.41
QR 7.53 ± 1.88# 7.43 ± 0.99 (57.7 ± 10.8) 0.22 ± 0.38 3.76 ± 0.47# 0.04 ± 0.40
RR 7.81 ± 1.98 7.56 ± 1.07 (59.1 ± 11.7) 0.19 ± 0.39 3.67 ± 0.48 0.02 ± 0.42
P value 0.0052 0.0022 0.016 0.0001 0.082
P for interactiona 0.059 0.26 0.022 0.0022 0.074
  1. Data are expressed as mean ± SD; P value refers to simple regression analysis
  2. # P < 0.05 vs. RR genotype
  3. aInteraction of statin therapy with PON1 genotype